The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The potential of selinexor combinations for RRMM

Jun 9, 2020

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Cristina Gasparetto, Duke University Cancer Center, Durham, US. In this video, she discusses the potential of selinexor combinations for relapsed/refractory multiple myeloma.

Cristina Gasparetto describes the mechanism of action of selinexor and the previous STORM study, which resulted in high toxicities. She then describes the results from the ongoing STOMP study that is comparing selinexor in combination with other backbone treatments. Dr Gasparetto describes the patient outcomes of the selinexor, dexamethasone and daratumumab arm and the selinexor, dexamethasone and carfilzomib arm. She also talks about the new dosing regimen that led to better tolerability and she concludes by discussing the response rate, progression-free survival and overall response rates.

The potential of selinexor combinations for RRMM